Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Jan. 14, 2021 11:00 UTC Primary endpoint was achieved, with dexpramipexole demonstrating a statistically significant reduction in blood eosinophil count over 12 weeks Reduction in blood eosinophil count correlated with clinically important improvement in lung function PITTSBURGH–(BUSINESS WIRE)–¬†Knopp Biosciences LLC¬†today … Continued